Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

GLP-1 weight loss drugs are proving beneficial for people struggling with obesity and diabetes, but there is another surprising side effect coming to light.

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...